Casdin Capital, Llc
- Regulatory AUM
- $2.9B
- Discretionary
- $2.9B
- Clients
- 7
- Avg AUM / client
- $410M
- Accounts
- 7
- Employees
- 29
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Mar 31, 2026
Investments (13F portfolio — 40 positions, $1,320,591,769)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc | COM | $250,645,634 | 2,577,333 | 19.0% | 8.73% |
| 2 | Genedx Holdings Corp | COM CL A | $193,120,072 | 3,007,164 | 14.6% | 6.72% |
| 3 | Relay Therapeutics Inc | COM | $143,464,811 | 14,418,574 | 10.9% | 4.99% |
| 4 | Biolife Solutions Inc | COM NEW | $113,662,708 | 5,957,165 | 8.61% | 3.96% |
| 5 | Standard Biotools Inc | COM | $81,618,999 | 88,783,856 | 6.18% | 2.84% |
| 6 | Illumina Inc | COM | $65,327,800 | 530,000 | 4.95% | 2.27% |
| 7 | Structure Therapeutics Inc | SPONSORED ADS | $56,635,000 | 1,175,000 | 4.29% | 1.97% |
| 8 | 10 X Genomics Inc | CL A COM | $48,298,250 | 2,275,000 | 3.66% | 1.68% |
| 9 | Denali Therapeutics Inc | COM | $35,328,000 | 1,840,000 | 2.68% | 1.23% |
| 10 | Beam Therapeutics Inc | COM | $32,170,500 | 1,350,000 | 2.44% | 1.12% |
| 11 | Guardant Health Inc | COM | $29,096,550 | 315,000 | 2.2% | 1.01% |
| 12 | Neurogene Inc | COM | $28,634,478 | 1,420,361 | 2.17% | 1.0% |
| 13 | Alnylam Pharmaceuticals Inc | COM | $24,815,250 | 75,000 | 1.88% | 0.86% |
| 14 | Maze Therapeutics Inc | COM | $22,651,881 | 758,857 | 1.72% | 0.79% |
| 15 | Scholar Rock Hldg Corp | COM | $17,206,000 | 350,000 | 1.3% | 0.6% |
| 16 | Agomab Therapeutics Nv | SPONSORED ADS | $16,259,500 | 1,550,000 | 1.23% | 0.57% |
| 17 | Hims & Hers Health Inc | COM CL A | $14,532,000 | 700,000 | 1.1% | 0.51% |
| 18 | Taysha Gene Therapies Inc | COM SHS | $14,527,500 | 3,250,000 | 1.1% | 0.51% |
| 19 | Qiagen Nv | ORD SHARES | $14,414,400 | 360,000 | 1.09% | 0.5% |
| 20 | Tempus Ai Inc | CL A | $13,300,423 | 294,127 | 1.01% | 0.46% |
| 21 | Septerna Inc | COM | $13,295,030 | 553,268 | 1.01% | 0.46% |
| 22 | Grail Inc | COM | $11,886,400 | 230,000 | 0.9% | 0.41% |
| 23 | Prime Medicine Inc | COM | $11,021,769 | 3,167,175 | 0.83% | 0.38% |
| 24 | Personalis Inc | COM | $10,192,000 | 1,600,000 | 0.77% | 0.35% |
| 25 | Quest Diagnostics Inc | COM | $9,799,000 | 50,000 | 0.74% | 0.34% |
Top 25 of 40 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 7 | $2.9B | 100.0% |
Private funds (6)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $2.6B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Casdin Partners Master Fund, L.P. master | Hedge Fund | Cayman Islands | $1.9B | 563 |
| Casdin Private Growth Equity Fund Ii, L.P. | Private Equity Fund | Delaware | $402M | 226 |
| Casdin Private Growth Equity Fund, L.P. | Private Equity Fund | Delaware | $243M | 175 |
| Casdin Venture Opportunities Fund, L.P. | Venture Capital Fund | Delaware | $28.5M | 46 |
| Casdin Partners Fo1 Msv, Lp | Hedge Fund | Delaware | $24.6M | 2 |
| Casdin Amplify Fund, Lp | Hedge Fund | Delaware | $13.6M | 2 |
People (5)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Casdin, Eli, D | Managing Member | Aug 2011 (15y) | 75% or more | |
| Canzoneri, Lawrence, Jude | Chief Financial Officer | May 2019 (7y) | Less than 5% | |
| Fisk, Alexandria | Chief Operating Officer | Jan 2020 (7y) | Less than 5% | |
| Crupi, Angelo | Chief Compliance Officer | Mar 2021 (5y) | Less than 5% | |
| Giordano, Steven, Michael | General Counsel | Mar 2022 (4y) | Less than 5% |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (6, $2.6B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Casdin Partners Master Fund, L.P. | Hedge Fund | $1.9B | $1.0M | 563 |
| Casdin Private Growth Equity Fund Ii, L.P. | Private Equity Fund | $402M | $1.0M | 226 |
| Casdin Private Growth Equity Fund, L.P. | Private Equity Fund | $243M | $1.0M | 175 |
| Casdin Venture Opportunities Fund, L.P. | Venture Capital Fund | $28.5M | $1.0M | 46 |
| Casdin Partners Fo1 Msv, Lp | Hedge Fund | $24.6M | $0 | 2 |
| Casdin Amplify Fund, Lp | Hedge Fund | $13.6M | $10.0M | 2 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 2.21 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports it does not have custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗